Podcasts about Allergy

Clonal mast cell disease is often missed because symptoms vary from person to person, tryptase levels can be normal, and bone marrow biopsies are hard to get. For some people, unexplained or very severe anaphylaxis may be an early sign of a clonal mast cell disease. In this episode, we review “Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation,” published in October 2025 in the Journal of Allergy and Clinical Immunology. This paper, known as the PROSPECTOR trial, is looking at how often the KIT D816V mutation can be found using a blood test in adults who have had anaphylaxis or systemic mast cell activation symptoms. We break down why KIT D816V matters, how it connects to systemic mastocytosis, why HaT needs to be considered, and how newer blood tests may help doctors catch clonal mast cell disease earlier. What we cover in our episode about KIT D816V and anaphylaxis: Setting the stage: Understanding mast cell activation and anaphylaxis. Why KIT D816V matters: How this mutation fits into clonal mast cell disease, what blood testing can reveal, and when doctors still turn to a bone marrow biopsy. Making sense of tryptase and hereditary alpha-tryptasemia (HaT): Why baseline tryptase, the “20% + 2” rule, and HaT can make screening more complicated than it seems. What the PROSPECTOR trial uncovered: How often KIT D816V appeared in people with anaphylaxis, and other results on tryptase and HaT. How this helps patients: What these findings mean for anyone with unexplained or severe anaphylaxis, and how doctors combine KIT testing, tryptase, HaT, and symptoms to decide on next steps. Other podcast episodes about mast cell disease: Ep. 127: Management of indolent mastocytosis - A clinical yardstick Ep. 126: Management of mast cell activation syndrome - A clinical yardstick Ep. 121: Avapritinib vs Placebo in Indolent Systemic Mastocytosis - PIONEER Trial Ep. 118: The ISM Disconnect - Do Patients and Providers Agree on Symptom Control? Ep. 70 How do stress and low histamine diets impact mast cell disease? Ep. 63: Mast Cell Diseases & Systemic Mastocytosis: The Basic Science Ep. 65: The Symptoms and Triggers of Mast Cell Disease *********** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider

The Rich Zeoli Show- Hour 4: 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a massive attempt to suppress the truth about Covid-19's origins. 6:40pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams.

The Rich Zeoli Show- Full Show (12/03/2025): 3:05pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams. 3:10pm- While speaking with the press on Tuesday, President Donald Trump called for a reduction of migrants from third world countries who are openly unwilling to assimilate to American culture. 3:20pm- Philadelphia Highway Patrol Officer Andy Chan has died six years after he was struck by a vehicle while on duty. Rich notes that Officer Chan was a friend of the show. Next Friday the show will be broadcasting from the 6th Annual Andy Chan Holiday Block Party. 3:30pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. 4:05pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 4:40pm- Carrie Severino—President of the Judicial Crisis Network (JCN) & Co-Author of the book, “Justice on Trial: The Kavanaugh Confirmation and the Future of the Supreme Court.”—joins The Rich Zeoli Show. On Tuesday, the U.S. Supreme Court heard oral argument in First Choice Women's Resource Centers v. Platkin. The case asks whether a federal court can hear First Choice's First Amendment challenge to a New Jersey investigatory subpoena when no state court has yet ordered the group to comply. While being questioned by Justice Clarence Thomas, NJ Attorney General Sundeep Iyer conceded that NJ hasn't received any public complaints to justify its subpoena against the pro-life health center. 5:05pm- A Washington Post report states that Department of War Secretary Pete Hegseth authorized a series of deadly strikes on a drug trafficking boat in the Caribbean, ordering military officials to “kill everybody.” The directive, according to the report, led to a second strike killing several crew members that survived the initial assault on the vessel. The New York Times, as well as the White House, dispute that Hegseth explicitly authorized the second strike or ordered to eliminate survivors. The NYT also reports that the “U.S. military intercepted radio communications from one of the survivors to what [officials] said were narco-traffickers.” 5:30pm- Following the Eagles loss to the Bears on Friday, Offensive Coordinator Kevin Patullo had his house egged. Does Justin have an alibi? Plus, a drunk racoon ransacked a convenience store! And “Be Nice to Matt Week” continues…sort of… 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a ma ...

In Australia, 1 in 10 families are navigating life with food allergies - and the anxiety that comes with keeping children safe can be overwhelming. In this essential conversation, Dr. Jodi Richardson welcomes Tamara Hubbard, founder of the Food Allergy Counselor and author of May Contain Anxiety: Managing the Overwhelm of Parenting Children with Food Allergies.Tamara is pioneering mental health support in food allergy care, helping families find what she calls the "just right balance" between anxiety and quality of life. As both a therapist specialising in food allergies and a parent who walks this path herself, she brings unique insight into the daily challenges families face - from label reading and school lunches to managing the fear of anaphylaxis.In this episode, you'll discover:Why anxiety is a natural part of food allergy management (and when it becomes overwhelming)The powerful "what if to if-then" strategy for managing worried thoughtsHow to determine what's safe, safe enough, and not safe for your childWhy avoidance can extend beyond what's medically necessaryThe importance of having your healthcare team answer key safety questionsHow families can live full, rich lives despite food allergy diagnosesWhether you're newly navigating a food allergy diagnosis, supporting someone who is, or simply want to understand what these families experience daily, this conversation offers hope, practical strategies, and validation for the very real challenges of keeping children safe while helping them thrive.Book Release: May Contain Anxiety is available now in North America in hardcover, paperback, e-book, and audiobook formats. Australian print editions are expected in early 2025, with digital versions available now.Connect with Tamara: Visit foodalergycounselor.com for resources, articles, and therapeutic worksheets, or follow @foodallergycounselor on social media.See omnystudio.com/listener for privacy information.

In this episode we dive into the strange and fascinating world of Alpha-gal syndrome (AGS), the delayed meat allergy that can appear after a tick bite. We talk through what AGS actually is, how ticks (lone star, blacklegged and western blacklegged ticks) introduce it into the body, and why some people develop an allergic reaction hours after eating red meat. You will hear about the symptoms people notice most often and the practical steps you can take to protect yourself from this unusual tickborne illness.Citations: A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner - PMCAbout Alpha-gal Syndrome | Alpha-gal Syndrome | CDCPreventing Tick Bites | Ticks | CDCWhat You Need to Know about PermethrinWhat to Do After a Tick Bite | Ticks | CDCRepellents: Protection against Mosquitoes, Ticks and Other Arthropods | US EPALegal:This podcast is for informational and educational purposes only and should not be taken as medical advice, diagnosis, or treatment. Nothing in this episode should be used to make decisions about your health without consulting a licensed physician or qualified healthcare professional. If you have questions about symptoms, allergies, prevention strategies, or medical conditions, please speak directly with your healthcare provider.All views expressed in this podcast are my own and do not represent the views of any current or past employers, academic institutions, or professional organizations. This podcast does not establish a clinician–patient relationship, and the use of the information discussed is at your own risk. If you are experiencing a medical emergency or severe allergic reaction, please seek immediate medical attention.

Bob Papa and Carl Banks preview the Monday Night Football matchup against the Patriots. With Mike Kafka shaking up the staff by firing Shane Bowen and elevating Charlie Bullen to interim defensive coordinator, they break down the changes fans should expect and why these moves matter for the team's future. They also dive into why playing strong down the stretch is critical and make the case for why Jaxson Dart needs more reps as the season unfolds. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I'm baaaaaaaaack For bookings: Whatsapp: 069 108 6174 email: kozmiq101@gmail.com

On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next.  Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next.  Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Allergies on the rise, epi pen access, childhood peanut exposure guidelines, and how allergens exposure doesn't mean let your child roll in the dirt. -o-www.everythingispublichealth.comBluesky Social: @everythingisPHMastodon: @everythingispublichealth Email: EverythingIsPublicHealth@gmail.com  Photo Credit: Photo by Diana Polekhina on UnsplashSupport the show

On episode #94 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 11/11/25 – 11/19/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus (Science Translational Medicine) Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice (CID) Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial (CID) HIV Pre-exposure Prophylaxis Does Not Increase Gonorrhea and Chlamydia Incidence in Young Black and Hispanic Men who Have Sex With Men: An Observational Cohort Study (OFID) Bacterial Global and regional knowledge of antibiotic use and resistance among the general public: a systematic review and meta-analysis (CMI: Clinical Microbiology and Infection) Infant Botulism Outbreak Linked to Infant Formula, November 2025 (CDC: Botulism) Outbreak Investigation of Infant Botulism: Infant Formula (November 2025) (FDA) Vitamin D deficiency at hospital admission with community-acquired pneumonia is associated with increased risk of mortality: A Prospective Cohort Study (OFID) Bat-Associated Hemotropic Mycoplasmas in Immunosuppressed Children, Spain, 2024 (Emerging Infectious Diseases) A Multicomponent Intervention to Improve Maternal Infection Outcomes (NEJM) Fungal The Last of US Season 2 (YouTube) Increasing Fluconazole Resistance in Candida parapsilosis: A 10-Year Analysis of Blood Culture Isolates at a US Reference Laboratory (2015–2024) (JID) British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update (LANCET: Infectious Diseases) In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment (JID) Parasitic Implications of a fatal anaphylactic reaction occurring 4 hours after eating beef in a young man with IgE antibodies to galactose-α-1,3-galactose (JACI: Journal of Allergy and Clinical Immunology In practice) WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization (WHO) Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi (LANCET: Global Health) A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication? (PLoS Neglected Tropical Diseases) Miscellaneous IL12RB1 deficiency appearing in North America: expanding the clinical phenotypes (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Look beyond viral suppression to learn how people living with virologically suppressed HIV may still be candidates for antiretroviral therapy (ART) switch to improve treatment satisfaction and quality of life. Topics covered include:Reasons to consider regimen optimization in setting of viral suppressionAvailable switch regimens, including 2-drug regimens and long-acting ARTApproaches to assess for resistance before starting long-acting cabotegravir plus rilpivirine DHHS recommendations on proviral DNA genotypingART optimization strategies for patients living with viral suppression and history of underlying resistancePresenters:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonCristina Mussini, MDProfessor of Infectious DiseasesChief of the Division of Infectious Diseases, Policlinico, ModenaUniversity of Modena and Reggio EmiliaModena, Italy Link to full program and accompanying slides: https://bit.ly/4pAI66gGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“It's kind of like we opened a Pandora's box and trying to close it up again is going to be very hard.” —Dr. Zachary RubinDr. Zachary Rubin joins Dr. Mariam Hanna for a candid look at the “difficult and misinformed” patient — the growing phenotype every allergist now manages weekly. A double board-certified pediatrician and allergist-immunologist with a massive social media footprint, Dr. Rubin breaks down how misinformation spreads, why it resonates, and how clinicians can approach these encounters without burning out or burning bridges. From TikTok-fuelled certainty to patients demanding full panels, he offers a practical, clinician-first playbook for navigating the mess.On this episode:Why today's misinformation is stickier, faster, and more emotionally charged than a decade ago, and how parasocial trust amplifies it.How the “nugget of truth” inside misinformation gives it power and how to dismantle it without escalating conflict.A clinic-ready strategy to approach resistant patients: open-ended questions, triaging what must be corrected now, and focusing on one actionable change at a time.Why continuity, follow-up, and small pieces of information over time often outperform a single “big correction.”How to use shared decision-making to reframe testing and treatment choices, especially when patients arrive convinced they need “the full panel.”Practical tools to support patient understanding, including targeted education resources, structured discharge summaries, and multimodal materials for different learning styles.How teams can protect each other through debriefs, preparation, and collaborative communication during high-stress encounters.A grounded, real-world conversation for clinicians who balance patient frustration, digital misinformation, and the realities of modern allergy practice.Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions

In this episode, host Dr. Kristine Smith speaks with Mr. James Bates. They discuss the recently published Original Article: “A Phase 1 Research Trial to Evaluate the Safety and Effectiveness of Intranasal Botulinum Toxin Type A Spray for Patients With Rhinitis.” The full manuscript is available in the International Forum of Allergy and Rhinology. Listen […]

Get all the inside secrets and tools you need to help you develop your intuitive and leadership skills so you are on the path to the highest level of success with ease. Christine Lauer shares about her journey from IT Computer Programmer to Laser Acupuncturist! In this episode you will learn:Quest for solutionsHow lasers balance imbalancesYES! It can be done remotelyAbout Christine:Christine has been a trusted Nutritionist and Acupuncturist since 2005, specializing in helping people find natural relief for allergies and sensitivities. Her journey began when her daughter developed severe eczema. When traditional remedies failed, Christine took matters into her own hands. By blending modern and ancient healing methods, she was able to help her spouse's seasonal allergies & her daughter's cat allergy, fueling her passion to helping others achieve lasting relief.Connect:Facebook: https://www.facebook.com/christinelauer1111 If you are ready to start reaching your goals instead of simply dreaming about it, start today with 12minutegift.com! Grab your FREE meditation: Reduce Your Anxiety MEDITATIONAre you ready to tiptoe into your intuition and tap into your soul's message? Let's talk Listen in as Jennifer Takagi, founder of Takagi Consulting, Certified High Performance Coach, 5X time Amazon.Com Best Selling-Author, Certified Soul Care Coach, Certified Jack Canfield Success Principle Trainer, Certified Professional Behavioral Analyst and Facilitator of the DISC Behavioral Profiles, Certified Change Style Indicator Facilitator, Law of Attraction Practitioner, and Certified Coaching Specialist - leadership entrepreneur, speaker and trainer, shares the lessons she's learned along the way. Each episode is designed to give you the tools, ideas, and inspiration to lead with integrity. Humor is a big part of Jennifer's life, so expect a few puns and possibly some sarcasm. Tune in for a motivational guest, a story or tips to take you even closer to that success you've been coveting. Please share the episodes that inspired you the most and be sure to leave a comment. Official Website: http://www.jennifertakagi.comInstagram: https://www.instagram.com/jennifertakagi/Facebook: facebook.com/takagiconsulting I look forward to connecting with you soon,Jennifer TakagiSpeaker, Trainer, Author, Energy HealerPS: We would love to hear from you! For questions, coaching, or to book interviews, please email my team at Jennifer@takagiconsulting.com

Fluent Fiction - Serbian: Botanist to Allergy Advocate: Danilo's Journey in Belgrade Find the full episode transcript, vocabulary words, and more:fluentfiction.com/sr/episode/2025-11-23-23-34-02-sr Story Transcript:Sr: Јесење сунце се пробијало кроз густе гроздове лишћа, обасјавајући Београдску ботаничку башту.En: The autumn sun filtered through the thick clusters of leaves, illuminating the Belgrade Botanical Garden.Sr: Ветрић је шапутао кроз разнобојне крошње дрвећа, а под ногама је крстарио осушеним лишћем, стварајући симфонију природе.En: A breeze whispered through the colorful tree canopies, and underfoot, dried leaves rustled, creating a symphony of nature.Sr: Дан у ботаничкој башти био је савршен за истраживање, али за Данила, страственог ботаничара, сваки корак је постајао све теже подношљив.En: The day at the botanical garden was perfect for exploring, but for Danilo, a passionate botanist, each step was becoming increasingly difficult to endure.Sr: Данило је већ дуго сумњао у свој избор каријере.En: Danilo had long been questioning his career choice.Sr: Љубав према биљкама и природи била је огромна, али алергије су биле његов непрекидни пратилац.En: His love for plants and nature was immense, but allergies were his constant companion.Sr: Упркос томе, остао је одлучан да оствари своју жељу – да открије нове биљне узорке и можда направи неки важан откриће.En: Despite this, he remained determined to fulfill his desire - to discover new plant specimens and perhaps make some significant discovery.Sr: Његова сестра, Мила, увек га је подржавала.En: His sister, Mila, always supported him.Sr: "Мислим да треба да пазиш на себе, Данило," рекла је забринуто кад је кренуо у башту без лека за алергију.En: "I think you need to take care of yourself, Danilo," she said worriedly when he headed to the garden without allergy medication.Sr: Али Данило је одлучио да ризикује.En: But Danilo decided to take the risk.Sr: Док је шетао шумовитим стазама, прилагођавајући се окружењу, Данило је узимао узорке.En: As he walked the wooded paths, adapting to the environment, Danilo collected samples.Sr: Са њим је био и његов колега Петар, који је често имао практична решења за све проблеме.En: With him was his colleague Petar, who often had practical solutions to all problems.Sr: "Слушај, Данило, ако се не осећаш добро, врати се," саветовао је Петар.En: "Listen, Danilo, if you're not feeling well, go back," advised Petar.Sr: Данило је био упоран.En: Danilo was persistent.Sr: "Још мало, Петре.En: "Just a little longer, Petar.Sr: Мислим да сам близу нечему.En: I think I'm close to something."Sr: "Али убрзо након тога, Данило је осетио тегобе.En: But soon after, Danilo felt unwell.Sr: Његово дисање је постало тешко, а срце му је убрзано куцало.En: His breathing became labored, and his heart raced.Sr: Алергијска реакција била је опака.En: The allergic reaction was severe.Sr: Петар је хитро реаговао, помагајући му да седне на најближу клупу.En: Petar quickly reacted, helping him to sit on the nearest bench.Sr: "Морамо да потражимо помоћ," рекао је хитро, а Данило је климнуо, принуђен да призна порекло своје невоље.En: "We need to seek help," Petar said urgently, and Danilo nodded, forced to acknowledge the cause of his trouble.Sr: Када је опасност прошла, и док је седео на клупи у врту, Данило је дубоко удахнуо и размислио о својој ситуацији.En: When the danger passed, and he was sitting on the bench in the garden, Danilo took a deep breath and contemplated his situation.Sr: Било је време за промену.En: It was time for a change.Sr: Озбиљно је прихватио своје стање и схватио да његова љубав према биљкама не мора да искључи пажњу на своје здравље.En: He seriously accepted his condition and realized that his love for plants didn't have to exclude attention to his health.Sr: Доневши одлуку, Данило је позвао Милу и Петра, говорећи им о својој новој идеји.En: Having made a decision, Danilo called Mila and Petar, telling them about his new idea.Sr: Уместо истраживања биљака, почеће да проучава алергије и њихове узроке.En: Instead of researching plants, he would start studying allergies and their causes.Sr: Његова мисија сада је била да помогне другим људима са истим проблемима.En: His mission now was to help other people with the same problems.Sr: "Увек сам говорила да природа има свој начин уређивања ствари," рекла је Мила са осмехом.En: "I always said nature has its way of arranging things," said Mila with a smile.Sr: Тако је, у шаренилу јесени у Београдској ботаничкој башти, Данило пронашао нови пут.En: Thus, amidst the autumn colors in the Belgrade Botanical Garden, Danilo found a new path.Sr: Његова страст је остала неизмењена, само сада је имао нову сврху - да помогне другима, као и себи, у борби са алергијама.En: His passion remained unchanged, only now he had a new purpose - to help others, as well as himself, in fighting allergies.Sr: Јесен је постала симбол новог почетка за њега.En: Autumn became a symbol of a new beginning for him. Vocabulary Words:filtered: пробијалоcluster: гроздillumination: обасјавањеbreeze: ветрићcanopy: крошњаunderfoot: под ногамаrustle: крстариsymphony: симфонијаpassionate: страственendure: подношљивallergy: алергијаspecimen: узоракsignificant: важанworriedly: забринутоrisk: ризикadapt: прилагођаватиpersistent: упоранlabored: тешкоsevere: опакacknowledge: признатиcontemplate: размислитиdetermined: одлучанbreathe: удахнутиmission: мисијаarranging: уређивањеamidst: у шаренилуunchanged: неизмењенpurpose: сврхаbeginning: почетакacknowledge: потврдити

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are dismayed by the changes on CDC vaccine website positively stating the link between autism and vaccination, the finding of wild type poliovirus 1 in Germany, Marburg virus in Ethiopia, decimation of the elephant breeding colony by H5N1 and the first human case of H5N5 influenza virus infection before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, antibody escape by seasonal flu viruses, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, if resistance exercise aids in recovery from long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Autism and Vaccines (CDC: Vaccine Safety) A new road to eradication- WPV 1 in Germany from Afghanistan (Reuters) Ethiopia confirms first outbreak of Marburg virus disease (WHO: Ethiopia) Highly Pathogenic Avian Influenza Viruses (HPAIV) Associated with Major Southern Elephant Seal Decline at South Georgia (Communications Biology) Avian flu has decimated world's largest breeding colony of southern elephant seals (CIDRAP) Washington resident is infected with a different type of bird flu (AP News) Pelagic Seabirds (OceanAminals) That sounds far away: Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals (Cell Reports) Regional voices, different choices: Parents' and caregivers' HPV vaccine attitudes in the northeast and Southeast United States (Vaccine) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025–2026 season (University of Toronto Press) Types of Influenza Viruses (CDC: Influenza (flu)) With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty (CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-word global database (Journal of Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 vaccination is associated with reduced complications in pediatric patients with atopic dermatitis (Annals of Allergy, Asthma and Immunology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) Risk mitigation of shared room ventilation and filtration on SARS-CoV-2 transmission: a multicenter test-negative study (Infection Control and Hospital Epidemiology) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Resistance Exercise Therapy After COVID-19 Infection(JAMA Open Network) Reaching out to US house representative Letters read on TWiV 1272 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists

Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists

Persistent congestion, pressure, or a reduced sense of smell often gets mistaken for allergies or a stubborn cold when it may be something more, like chronic rhinosinusitis with nasal polyps (CRSwNP). Getting the right diagnosis is the first step toward real relief. Dr. Tonya Farmer, a board-certified ENT, joins Kortney and Dr. G to explain how chronic rhinosinusitis with nasal polyps (CRSwNP) is diagnosed. She walks us through the full evaluation: what symptoms matter, what a nasal endoscopy actually shows, when a CT scan is needed, and how type 2 inflammation fits into the picture. What we cover about diagnosing CRSwNP: Key symptoms: Persistent congestion, drainage, facial pressure, and especially loss of smell are major red flags for CRSwNP. Why duration matters: Chronic means 12 weeks or longer. If symptoms keep coming back or never truly improve, it's time to look deeper. The physical exam: ENTs use nasal endoscopy to see swelling, mucus, or polyps that aren't visible from the outside. When CT scans are needed: Imaging helps confirm sinus inflammation and shows the extent of polyp growth. Additional testing: Allergy testing, IgE levels, eosinophils, and other immune markers help identify type 2 inflammation and guide next steps. When to see a specialist: If antibiotics, steroids, or over-the-counter treatments aren't helping, ask for a referral to an allergist or ENT. Early diagnosis can prevent worsening symptoms and reduce the need for surgery. Set the foundations: Ep. 133: What is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)? ___   Made in partnership with The Allergy & Asthma Network. Thanks to Sanofi for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

First death related to red meat allergy triggered by tick bites Learn more about your ad choices. Visit megaphone.fm/adchoices

Hardware is… easy now?! That's what Matt Truebe said when he pitched three devices and a plan to help families with food allergies and asthma. He has tons of experience, but between telehealth and hardware, is this business just too complicated for the VCs? This is The Pitch for Above Health. Featuring investors Cyan Banister, Charles Hudson, Immad Akhund, Monique Woodard, and Rohit Gupta. ... Watch Matt's pitch uncut on Patreon (@ThePitch) Subscribe to our email newsletter: insider.pitch.show Learn more about The Pitch Fund: thepitch.fund *Disclaimer: No offer to invest in Above Health is being made to or solicited from the listening audience on today's show. The information provided on this show is not intended to be investment advice and should not be relied upon as such. The investors on today's episode are providing their opinions based on their own assessment of the business presented. Those opinions should not be considered professional investment advice. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Earlier this month, more than 2,500 allergists and healthcare professionals gathered in Orlando, Florida, for the annual meeting of the American College of Allergy, Asthma & Immunology—better known as ACAAI. It's one of the biggest events of the year where experts share the latest research, treatments, and guidelines in allergy and immunology. We're thrilled to be joined by this year's keynote speaker, program chair—and FAACT Medical Board Member—Dr. Kristin Sokol, MD, MS, MPH, who shares highlights and key takeaways from this cutting-edge meeting.Resources to keep you in the know:American College of Allergy Asthma and Immunology (ACAAI)Schreiber Allergy: Kristin Sokol, M.D., MS, MPH, FACAAI, FAAAAIYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: GenentechThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

In this episode, we tackle the challenge of separating allergy fact from fiction in an age of rampant online misinformation. Dr. Zachary Rubin, a double board-certified pediatrician and allergist, shares insights on common allergy myths circulating on social media. We explore misconceptions about food allergies vs. intolerances, respiratory allergies, eczema management, anaphylaxis treatment, and allergy testing interpretation. Learn how to navigate patient conversations about gluten sensitivity, pet allergies, and "natural" allergy cures. This episode provides primary care clinicians with practical strategies to address patient concerns rooted in online misinformation and optimize allergy diagnosis and management in clinical practice.

Join Dr. Nicholas Cline and host Marcella Feathers as they discuss the reintroduction of the Penicillin Allergy Verification and Evaluation (PAVE) Act.  The PAVE Act would require physicians to verify a penicillin allergy during the "Welcome to Medicare" preventive visit and annual Medicare wellness visits.  Penicillin was discovered in 1928 by Alexander Fleming and is an inexpensive but very effective antibiotic. Dr. Cline shares why the majority of patients who believe they're allergic to penicillin may have an inaccurate diagnosis and what options are available for determining if an allergy actually exists. Whether or not you're a Medicare patient, confirming a penicillin allergy can save you money and time!

Send me a question or story!As dermatologists, we LOVE topical therapy. However there are some basic things that need to be considered when suggesting a protocol. What are you treating?What is the ultimate goal?What do you or the owner have?Can it happen?Check out some simple tips on this week's episode of The Derm Vet podcast!00:00 – Intro01:15 – Q1: Why Are You Using Topical Therapy?04:41 – Q2: What is the Goal of the Product?05:58 – Q3: What Do You Have Available?08:45 – Q4: Can the Owner Do It?11:34 – Overview12:44 – Outro

The tickborne illness alpha-gal syndrome affects what you can eat. For those who contract it, mealtime becomes a minefield. Plus: American agriculture depends on foreign workers, but President Donald Trump's immigration clampdown is shrinking a farm workforce that many say was already too small.

Avoidance has long been the standard for managing food allergies. But new options, such as oral immunotherapy (OIT) and biologic medications like Xolair (omalizumab), are changing the landscape. With more choices available, many patients and parents are wondering how to start the conversation with their allergist and what questions to ask. Kortney and Dr. Payel Gupta talk with Dr. Shahzad Mustafa, a board-certified allergist and immunologist, about how patients can navigate today's food allergy treatments with confidence. Together, they explore what to consider before starting OIT or Xolair, how to set realistic expectations, and why strict avoidance is still the right choice for many families. What we cover about food allergy treatment options: Food Allergy Avoidance: Why it remains an effective and valid approach for many, and how to make it work in daily life, including the nuances that make every case unique. Oral Immunotherapy (OIT): What it involves, who it's best suited for, and what families should know about time, cost, and safety. Xolair (omalizumab): How this injection therapy works to reduce reactions from accidental exposures and what it doesn't do. Setting expectations: How to talk with your allergist about your goals, quality of life, and what “success” really looks like. More episodes about food allergies Ep. 129: Omalizumab for Multiple Food Allergies – The OUtMATCH Trial Ep. 98: Food Allergy Treatment and Management More resources about food allergies Food Allergy Treatment & Management ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.  

FULL SHOW: Tuesday, November 11th, 2025 Curious if we look as bad as we sound? Follow us @BrookeandJeffrey: Youtube Instagram TikTok BrookeandJeffrey.comSee omnystudio.com/listener for privacy information.

Nothing ruins a nature walk like a tick bite, and scientists say concerns from those bites are growing beyond Lyme disease. Brad Kutner has this report on a new study out of Virginia Commonwealth University. 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

Can anxiety about food safety quietly shape the way an entire family eats, lives, and loves? In this episode of Dr. Marianne-Land: An Eating Disorder Recovery Podcast, Dr. Marianne Miller, LMFT, talks with Tamara Hubbard, LCPC, founder of The Food Allergy Counselor and The Academy of Food Allergy Counseling. Together, they explore how food allergy anxiety can affect both children and parents, sometimes leading to ARFID-like eating patterns and significant emotional distress. Tamara shares her journey from being a parent of a child with a peanut allergy to becoming a national leader in the field of food allergy mental health. She discusses how chronic fear and misinformation can cause families to become trapped in cycles of hypervigilance and restriction. She and Dr. Marianne also examine how therapy can help families move toward flexibility, autonomy, and connection at the table. Listeners will hear how Acceptance and Commitment Therapy (ACT) and values-based approaches support parents in balancing safety with freedom, and how addressing anxiety can improve both emotional well-being and quality of life. Key Topics Covered The difference between food allergies and food intolerances and why accurate understanding matters How food allergy anxiety can spread through families and mimic ARFID symptoms The role of parental fear in shaping a child's own food relationship and daily life The risks of restriction-based medical advice, including some functional medicine practices How ACT and mindfulness tools can help parents tolerate fear and stay connected to their values Ways to calm the fight-or-flight response and reduce hypervigilance around food and safety Why collaboration between therapists and allergists creates stronger, safer support for families Who This Episode Is For This episode is for parents and caregivers who want to understand how food allergies, anxiety, and ARFID intersect in family life. It is also for therapists, dietitians, and healthcare providers who want to learn how to support families with evidence-based, trauma-informed, and values-driven care. Food Allergy Resources Mentioned Book: May Contain Anxiety: Managing the Overwhelm of Parenting Children With Food Allergies by Tamara Hubbard, LCPC (Johns Hopkins University Press, 2025) Website: The Food Allergy Counselor for educational articles, therapeutic resources, and directories of food allergy-informed therapists Organization: The Academy of Food Allergy Counseling for clinician training and professional community Article: Allergic Living Magazine Airline Allergy Travel Guide for details on how major airlines handle food allergy policies Advocacy Resource: No Nut Traveler by Leanne Mandelbaum, advocating for safer air travel for people with food allergies Therapeutic Framework: Acceptance and Commitment Therapy (ACT) for managing anxiety and values alignment Cultural Reference: We Can Do Hard Things by Glennon Doyle as a reminder of resilience and self-compassion Content Caution This episode includes discussions of allergic reactions, anaphylaxis, and eating challenges. Please take care while listening if these topics may feel activating or distressing. Learn More and Get ARFID and Selective Eating Support Visit ARFID and Selective Eating Course. This virtual program provides a compassionate, neurodivergent-affirming framework that helps families and clinicians create safety, flexibility, and understanding around food.

"Wrap up warm, or you'll catch a cold!" No doubt you heard that advice a lot as a child, and you may well still hear it as an adult. For a long time, scientists were skeptical about the idea that simply being exposed to the cold could make a person sick. After all, to get sick, you need to actually come into contact with a microbe, like a virus. And cold weather itself isn't a disease. But recent developments suggest there may actually be some truth to the idea. In December 2022, The Journal of Allergy and Clinical Immunology published a study by a team of American researchers, who had looked into how cold weather affected immunity in the nose. The researchers explained that our nasal mucous membranes, and in particular the extracellular vesicles, act as the first line of defense in our immune system against viral attacks. What do we know now that we didn't before? But is the cold the sole culprit? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠How can I limit the effects of sugar on my health?⁠ ⁠What happens to your online life after you die?⁠ ⁠Why does cooking benefit our mental health?⁠ A podcast written and realised by Joseph Chance. First Broadcast: 24/9/2024 Learn more about your ad choices. Visit megaphone.fm/adchoices

When it comes to keeping kids with food allergies safe at school, school nurses are often the quiet heroes behind the scenes. From managing allergy action plans and emergency responses to training teachers and organizing care for hundreds of students, their role is essential, but often misunderstood. Kortney and Dr. Payel Gupta sit down with Elizabeth Elliott, a school nurse and President of the Maryland Association of School Health Nurses. Liz shares what really happens inside the health room and how school nurses coordinate care for students with food allergies and asthma. Plus, why communication between families and school staff is key to keeping kids safe. After this episode, you'll have a whole new appreciation for your school nurse and a better understanding of how to partner with them to make every school day safer for kids with allergies. What we cover about food allergy management at school: The school nurse's role: How nurses bridge communication between families, teachers, and doctors to keep children with food allergies safe and included during the school day. Coordinating care: How school nurses use action plans and 504s to ensure everyone, from teachers to cafeteria staff, knows how to keep kids safe. Training and emergency preparedness: How school nurses teach staff to recognize anaphylaxis, use epinephrine, and stay calm during an emergency. Field trips, cafeterias, and bus safety: What goes into planning safe experiences beyond the classroom, and why “no-food on the bus” rules really matter. Advocating for resources: How families can support their school nurses and advocate for better funding, staffing, and allergy awareness in schools. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

In episode 135 of Nonprofit Mission: Impact, Carol Hamilton talks with organizational design consultant Julian Chender about how nonprofits can move beyond simple restructuring to intentional organizational design that aligns strategy, structure, and process.  They discuss: how organizational design is not the same as restructuring how design choices impact effectiveness, collaboration, and long-term sustainability.  the pitfalls of designing around personalities,  the importance of strategic clarity when facing downsizing or merger decisions.  The conversation offers nonprofit leaders practical insights into building organizations that are resilient, adaptable, and positioned for impact.   Episode highlights: The Why Behind the Work -  [00:08:08]  Defining Organizational Design - [00:13:53]  Structure, Silos, and Collaboration - [00:14:41]  Common Mistakes in Nonprofit Design -  [00:18:23]  Balancing Human-Centered Values and Strategy -  [00:20:40]  Downsizing by Design - [00:24:36]  Participation and Ownership - [00:23:32]  Benchmarking vs. Mass Customization -  [00:30:01]  Strategic Plans Require Organizational Design - [00:37:40] Mergers and Strategic Alliances -  [00:41:21]  Examples of Successful Mergers -  [00:44:16]  The Key Question for Leaders - [00:47:57]    Guest Bio: Julian Chender is the founder of 11A Collaborative, an organization design firm focused on creating healthy society through healthy organizations. In his early years, Julian was an internal consultant at the National Institute of Allergy and Infectious Disease (NIAID) under Tony Fauci during the agency's response to the global Ebola and Zika crises. From there, he moved to external consulting, eventually joining Accenture's Operating Model & Organization Design practice shortly after its acquisition of Kates Kesler. Through 11A Collaborative, Julian has consulted to purpose-driven organizations across sectors. He is a Certified Organization Design Practitioner and an ICF-Certified Coach who holds a master's degree in Organization Development from American University and a B.A. in History from Swarthmore College. Important Links and Resources: Julian Chender 11A Collaborative Organization Design Forum Downsizing by Design: A Guide for Nonprofits Candid Social Impact Staff Retention survey Board Source Purpose Driven Leadership   Be in Touch: ✉️ Subscribe to Carol's newsletter at Grace Social Sector Consulting and receive the Common Mistakes Nonprofits Make In Strategic Planning And How To Avoid Them

For years, doctors warned parents to keep peanuts away from children until they turn three. But that advice backfired. Experts now say delayed exposure helped cause a peanut allergy surge in the U.S. Lessons for public health from peanut allergy advice.

Did you know that a dog allergy could be linked to unexplained infertility? This episode delves into fascinating allergy case studies and how component-resolved diagnostics can help uncover hidden connections. From wheat-dependent exercise-induced anaphylaxis in children to severe sesame reactions despite negative clinical history, learn what these interesting cases can teach us about the impact of allergen component sensitization and how innovative testing using components can broaden our understanding. This episode also explores the latest insights into wheat and sesame allergen components as well as how these tools can enhance your clinical decision-making, improve diagnostic accuracy, and optimize allergy management strategies. For episode resources and references, visit: https://www.thermofisher.com/phadia/us/en/resources/immunocast/allergy-case-studies-component-diagnostics-dog-sensitization-wheat-allergy-sesame-reactions.html?cid=0ct_3pc_05032024_9SGOV4

I recently had an ApoB test and am surprised that it isn't lower than it is.  Can you explain?I have an ascending thoracic aortic aneurysm.  How can I keep it from enlarging?Why are you against whole-body scans? Aren't they helpful?Can I take magnesium L-threonate while also taking magnesium glycinate?

Will Truheight vitamins really make your kids grow?Where can I learn more about complementary medicine and nutrition?The balls of my feet are sore along with my toes. Is this a vitamin deficiency?

Mucus plugging is a challenge in asthma care. It's thick, sticky mucus that blocks the airways and doesn't respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control. In this episode, we break down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published October 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.” What we cover in our episode about dupilumab and mucus plugging Why mucus plugging matters in asthma: Discover how thick, sticky mucus can block airways, make it harder to breathe, and why standard inhalers and steroids don't clear these plugs. How dupilumab may help: Learn how this biologic blocks IL-4 and IL-13, two key drivers of type 2 inflammation that increase mucus production and thickness. Inside the VESTIGE study: Hear how researchers measured mucus burden using CT scans and “mucus plug scores” to see if dupilumab could reduce plugging in moderate-to-severe asthma. What the results showed: Find out how dupilumab lowered mucus plug scores, reduced airway inflammation, and improved lung function (FEV₁), especially in people with high mucus burden. What this means for patients: Learn why identifying and treating mucus plugging may help improve breathing, reduce flare-ups, and make asthma easier to manage day to day.

For decades, peanut allergies were on the rise in the US. But a study released on October 20 found that peanut allergies in babies and young children are now decreasing. This drop correlates with a change in guidance from the National Institute of Allergy and Infectious Diseases. In 2017, the agency started recommending exposing children to peanuts “early and often.” Since that recommendation, the prevalence of peanut allergies has dropped significantly.Sharon Chinthrajah, a physician specializing in allergies and immunology, churns through the findings with Host Flora Lichtman.  Guest: Dr. Sharon Chinthrajah is a physician specializing in allergy and immunology at the Sean N. Parker Center at Stanford University.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Want to heal your child's eczema without steroids and save $200 this week? Click here to get started → EczemaKids.com Use code EPISODE200 to get $200 off the Eczema Elimination Method.... the COMPLETE eczema-reversal system that actually works. This offer is good for one week only and ends Tuesday, November 4th, 2025. If your child's ever had an allergy test hoping for answers, only to walk out more confused or flaring, this episode is for you. As we celebrate 200 episodes (and my birthday week!), I'm breaking down what allergy tests actually measure, why kids with eczema often react badly, and how to tell the difference between true, serious IgE allergies and immune overload. We'll talk about why scratch tests and immunotherapy often do more harm than good for eczema families, what to do if your child already flared after testing, and how to start healing their skin and gut from the inside out.

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest:  Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices

Research from the last decade of food allergies, shows that updated guidance had made a real impact on the number of people with allergies. Read more about the research here  ★ Support this podcast on Patreon ★

Millions of people around the world were impacted by a major internet outage today, but an expert says it could have been much worse. Senators are returning to Capitol Hill today, with no compromise in sight to end the shutdown. President Donald Trump says tariffs are coming for Colombia. The FBI is investigating a “suspicious” hunting stand near Florida's Air Force One landing zone. Plus, some good news on preventing peanut allergies. Learn more about your ad choices. Visit podcastchoices.com/adchoices

These diseases - West Nile Virus, Lyme disease, and Rocky Mountain Spotted Fever - are named for the places where outbreaks happened. But they're also all things you get from being bitten by mosquitoes or ticks. Research: Balasubramanian, Chandana. “Rocky Mountain Spotted Fever (RMSF): The Deadly Tick-borne Disease That Inspired a Hit Movie.” Gideon. 9/1/2022. https://www.gideononline.com/blogs/rocky-mountain-spotted-fever/ Barbour AG, Benach JL2019.Discovery of the Lyme Disease Agent. mBio10:10.1128/mbio.02166-19.https://doi.org/10.1128/mbio.02166-19 Bay Area Lyme Foundation. “History of Lyme Disease.” https://www.bayarealyme.org/about-lyme/history-lyme-disease/ Caccone, Adalgisa. “Ancient History of Lyme Disease in North America Revealed with Bacterial Genomes.” Yale School of Medicine. 8/28/2017. https://medicine.yale.edu/news-article/ancient-history-of-lyme-disease-in-north-america-revealed-with-bacterial-genomes/ Chowning, William M. “Studies in Pyroplasmosis Hominis.("Spotted Fever" or "Tick Fever" of the Rocky Mountains.).” The Journal of Infectious Diseases. 1/2/1904. https://archive.org/details/jstor-30071629/page/n29/mode/1up Elbaum-Garfinkle, Shana. “Close to home: a history of Yale and Lyme disease.” The Yale journal of biology and medicine vol. 84,2 (2011): 103-8. Farris, Debbie. “Lyme disease older than human race.” Oregon State University. 5/29/2014. https://science.oregonstate.edu/IMPACT/2014/05/lyme-disease-older-than-human-race Galef, Julia. “Iceman Was a Medical Mess.” Science. 2/29/2012. https://www.science.org/content/article/iceman-was-medical-mess Gould, Carolyn V. “Combating West Nile Virus Disease — Time to Revisit Vaccination.” New England Journal of Medicine. Vol. 388, No. 18. 4/29/2023. https://www.nejm.org/doi/full/10.1056/NEJMp2301816 Harmon, Jim. “Harmon’s Histories: Montana’s Early Tick Fever Research Drew Protests, Violence.” Missoula Current. 7/20/2020. https://missoulacurrent.com/ticks/ Hayes, Curtis G. “West Nile Virus: Uganda, 1937, to New York City, 1999.” From West Nile Virus: Detection, Surveillance, and Control. New York : New York Academy of Sciences. 2001. https://archive.org/details/westnilevirusdet0951unse/ Jannotta, Sepp. “Robert Cooley.” Montana State University. 10/12/2012. https://www.montana.edu/news/mountainsandminds/article.html?id=11471 Johnston, B L, and J M Conly. “West Nile virus - where did it come from and where might it go?.” The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 11,4 (2000): 175-8. doi:10.1155/2000/856598 Lloyd, Douglas S. “Circular Letter #12 -32.” 8/3/1976. https://portal.ct.gov/-/media/departments-and-agencies/dph/dph/infectious_diseases/lyme/1976circularletterpdf.pdf Mahajan, Vikram K. “Lyme Disease: An Overview.” Indian dermatology online journal vol. 14,5 594-604. 23 Feb. 2023, doi:10.4103/idoj.idoj_418_22 MedLine Plus. “West Nile virus infection.” https://medlineplus.gov/ency/article/007186.htm National Institute of Allergy and Infectious Disease. “History of Rocky Mountain Labs (RML).” 8/16/2023. https://www.niaid.nih.gov/about/rocky-mountain-history National Institute of Allergy and Infectious Disease. “Rocky Mountain Spotted Fever.” https://www.niaid.nih.gov/diseases-conditions/rocky-mountain-spotted-fever Rensberger, Boyce. “A New Type of Arthritis Found in Lyme.” New York Times. 7/18/1976. https://www.nytimes.com/1976/07/18/archives/a-new-type-of-arthritis-found-in-lyme-new-form-of-arthritis-is.html?login=smartlock&auth=login-smartlock Rucker, William Colby. “Rocky Mountain Spotted Fever.” Washington: Government Printing Office. 1912. https://archive.org/details/101688739.nlm.nih.gov/page/ Sejvar, James J. “West Nile virus: an historical overview.” Ochsner journal vol. 5,3 (2003): 6-10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3111838/ Smithburn, K.C. et al. “A Neurotropic Virus Isolated from the Blood of a Native of Uganda.” The American Journal of Tropical Medicine and Hygiene. Volume s1-20: Issue 4. 1940. Steere, Allen C et al. “The emergence of Lyme disease.” The Journal of clinical investigation vol. 113,8 (2004): 1093-101. doi:10.1172/JCI21681 Steere, Allen C. et al. “Historical Perspectives.” Zbl. Bakt. Hyg. A 263, 3-6 (1986 ). https://pdf.sciencedirectassets.com/281837/1-s2.0-S0176672486X80912/1-s2.0-S0176672486800931/main.pdf World Health Organization. “West Nile Virus.” 10/3/2017. https://www.who.int/news-room/fact-sheets/detail/west-nile-virus Xiao, Y., Beare, P.A., Best, S.M. et al. Genetic sequencing of a 1944 Rocky Mountain spotted fever vaccine. Sci Rep 13, 4687 (2023). https://doi.org/10.1038/s41598-023-31894-0 See omnystudio.com/listener for privacy information.